Disclaimer: This is not medical advice. I am  just documenting my GLP-1 journey.

Part 3: Insurance Gatekeeping, GLP-1s, and the Feeling of Having to Earn Care

One thing I did not fully understand before starting my GLP-1 journey was how much of the process would involve insurance companies deciding whether I deserved treatment. After taking more than a year to decide to start this process, I assumed my insurance company would cover this life-changing medication. I researched different GLP-1 medications extensively. I had friends on one that was very popular and now comes in pill form, and honestly, I wanted that option because the idea of giving myself a weekly shot in my thigh, arm, or stomach was frightening.

What ultimately made me settle on the GLP-1 I am currently taking was the fact that my insurance company had covered it for my daughter when she was still on my medical insurance plan. In my mind, if all else failed, I could at least feel confident I would have access to one of these medications.

Imagine my surprise when I found out I would have to pay a whopping $495.00 copay for this medication. Still, it was not a complete shock. During my yearly physical, when I requested the medication, my Primary Care Physician (PCP) warned me that some insurance companies were no longer covering these medications and that we could discuss alternatives. Even then, I felt certain my insurance would cover me. My daughter was no longer taking the medication, but I thought, I’m good, and said a few prayers.

When I received the pharmacy robocall informing me that my prescription was ready, I anxiously tapped through the prompts to hear the amount of my copay. I was floored when I found out the cost. I immediately pressed the customer service buttons to speak with the pharmacist, who explained that my insurance would only cover about half the cost and suggested I contact the insurance company to find out why.

From there, when I followed up with the insurance company, one of the options in the prerecorded message instructed insured members which number to call for GLP-1 medication preauthorization. I thought, WTF? What about this medication required preauthorization? Over the past year, while researching the medication for myself, I came to view it as a godsend for many people struggling to lose weight. I had watched two of my good friends achieve incredible success with weight loss, looking and feeling better, and improving numbers at the doctor’s office, including lower blood pressure, lower blood sugar, and improvements in other comorbidity conditions associated with obesity.

After speaking with a representative, I learned that as of February 2026, my insurance company had started a gatekeeping preauthorization process for GLP-1 medications. I was instructed to download an app and onboard into a utilization management program managed by a company authorized by my insurance provider to determine whether I could qualify for this medication.

Now, anyone insured through this company seeking healthcare improvement through GLP-1 medications had to complete a mandated “12-week health journey” involving generic medication trials if deemed appropriate, coaching calls, weigh-ins on a connected scale, and ongoing monitoring. After the three-month process, a provider would decide whether the medication was appropriate for me. In other words, whether I had earned the right to access medical care through an insurance company I already pay hard-earned monthly premiums to for this exact purpose: helping cover the high cost of healthcare and medication. Every part of this process was communicated through AI-generated messages in the app.

I was fuming. It felt like another roadblock standing between me and improving my health. It felt like I had finally decided to move forward with this health-changing process, only to run straight into another barrier. More importantly, this was my own insurance company, collecting monthly premiums from my paycheck to offset the cost of wellness and care, now deciding whether I was worthy of receiving medicine prescribed by my PCP. They were deciding whether I had earned access to something that could improve my health. It felt like putting money into a bank only to be told the bank would decide if and when you could withdraw your own money and what you were allowed to spend it on.

I knew that the monitoring processes were not entirely new with GLP-1 prescriptions. My friends who were already taking these medications had check-ins and weigh-ins, but they were at least prescribed the medication at the beginning of the process and participated in the monitoring while already receiving care. That difference mattered. This felt like judgment upfront, like I had to prove I could succeed or not before I was even allowed to have access. At the same time, it ignored the reality that if I truly believed I could do this completely on my own, without the help of this GLP-1 support, I would not be here seeking help.

I am also not blind to the explosion in GLP-1 use. After deciding to go through this process, I started researching why insurance companies were responding in this way. What I found was that as medications like Ozempic, Wegovy, and Zepbound became more popular, insurers responded with stricter approval systems because these medications changed the entire conversation around obesity and weight management. For many people, they were the first thing that worked after years of failed diets, exercise plans, calorie counting, shame, regain cycles, and metabolic struggles. These medications were not cosmetic for many patients. They represented hope after years of frustration.

But that success also came with an enormous financial impact. Many GLP-1 medications cost more than $1,000 a month without insurance, and employer health plans began reporting major increases in spending tied to these prescriptions (WTW, 2024). As demand exploded between 2023 and 2024, insurance companies responded with tighter prior authorizations, BMI requirements, mandatory coaching programs, step therapy requirements, proof of failed attempts, recurring check-ins, nutrition tracking apps, and telehealth monitoring systems. I understand why insurers felt pressure to manage costs and demand via utilization management systems, but for patients like me, it feels more like gatekeeping.

My insurance company is now among many requiring proof of effort and participation in digital health programs, nutrition tracking, telehealth coaching, or ongoing compliance monitoring (KFF, 2024) before approving this life-changing medication. The message may be unspoken, but it feels clear: prove you are trying hard enough first, or prove that you cannot do it on your own. I am not sure which one, but that is what I hear, and that is what I feel in this entire process.

As I continued researching, I also became more aware of how quickly everything changed. Originally, medications like Ozempic were primarily prescribed for type 2 diabetes. Then clinical trials showed newer GLP-1 medications could produce weight loss of 15 to 20 percent of body weight, far exceeding older obesity medications (Reuters, 2024). Almost overnight, demand surged. Social media amplified awareness, celebrity use increased visibility, employers saw prescription costs skyrocket, and insurers realized millions more people could qualify.

That was when insurance companies began building larger utilization management systems involving prior authorizations, mandatory programs, and recurring evaluations. Some plans restricted coverage to diabetes only, while others added stricter requirements during each renewal cycle (KFF, 2024). But for patients, it often feels like this: you finally found something that works, and now you have to prove you deserve it through systems designed by people who are not living your reality.

For the last six weeks, I have been participating in this insurance-mandated, gatekeeping utilization management program. Every time I logged in or completed another step, I found myself repeating the same thought: “I am only here because my insurance company requires it so I can access a life-changing medication,” motivating myself to stay the course even though, in the end, they may still not authorize the coverage. I feel trapped into complying, even though I am extremely frustrated. Maybe that sounds dramatic, but it honestly reflects how I felt.

The program, of course, includes nutrition tracking, telehealth check-ins, coaching interactions, and compliance checkpoints that must be completed to remain eligible. At times, the experience feels less like healthcare and more like standardized monitoring, where progress is measured by task completion rather than personal context. I kept thinking about people who have already spent years cycling through diets, workouts, calorie counting, frustration, and shame before ever reaching a program like this. At some point, it stops feeling like healthcare and starts feeling like permission-seeking.

Many insurers and employers now partner with digital health platforms and virtual obesity-management programs to manage GLP-1 access and costs. These programs often combine telehealth, coaching, nutrition tracking, and prior authorization support. The stated goal of these programs is to improve outcomes and reduce unnecessary prescribing, but for patients, the experience can feel impersonal and overly standardized.

I am not saying this program has no value because I have learned things from it, mostly through videos and AI-based interactions. But I have also done the work outside of it. I have seen my doctor. I have struggled with this for years. I have meal-prepped, weight trained, exercised, and tried to stay consistent. At a certain point, it starts to feel like the system is not fully recognizing that effort or the reality of what I am dealing with. It would help if there were more acknowledgment that people are already stuck in difficult cycles and are not simply looking for information, but genuine support in breaking through them.

I do understand why insurance companies created these systems. Demand for GLP-1 medications like Ozempic, Wegovy, and Zepbound increased rapidly after studies showed dramatic weight loss results, often far beyond older medications (Reuters, 2024). Employers and insurers quickly realized how many people could qualify, and financially, that surge created pressure that led to prior authorizations, mandatory programs, digital tracking, and recurring evaluations. In theory, the intent is to ensure appropriate prescribing and control costs.

The stated goal is accountability and responsible prescribing. But in practice, it can feel less like support and more like surveillance, especially for people who have already spent years trying to manage weight on their own.

I want these insurance companies to understand that obesity is not just a math problem. It is not just calories or discipline. For many people, it involves years of biology, metabolism, stress, hormones, injuries, emotional eating, failed attempts, and exhaustion. Systems should leave room for that reality instead of reducing people to checklists that do not fully reflect what they are actually living through.

Needless to say, I am currently paying a significant out-of-pocket cost on a monthly basis to access this medication, hoping that after this three-month process, my insurance will finally help cover the cost of what has become, for me, a life-changing treatment. Some people say these programs exist to determine whether you are truly struggling and cannot do it on your own before approving coverage. But eventually, I think people reach a crossroads. Do you wait for insurance companies to decide while your health potentially deteriorates, or take the chance and try this medication that has already proved successful at helping with obesity, high blood pressure, high blood sugar, and joint pain? I chose to take the risk of the financial burden myself, like so many others have had to do with other life-saving medications, simply trying to improve their health, live longer, and sometimes just survive.

Who knows how long I will be able to afford this. I genuinely hope my insurance company comes through because helping cover healthcare is what we pay insurance companies to do. The biggest thing I am learning is that weight loss is more complicated than I originally thought, but so is healthcare access. Sometimes the hardest part is not taking the medication. Sometimes the hardest part is navigating the systems standing between patients and the treatment that could help them.

I also believe there has to be a middle ground where medications are prescribed responsibly without making patients feel interrogated or reduced to checklists. People should not have to perform suffering to receive care. If someone has struggled for years, meet them there. Healthcare systems need to get better at recognizing the difference between accountability and compassion.

Today, I am down 15 pounds. The hardest part was not learning how to lose weight. It was learning how many systems stand between patients and treatment once something finally starts working, and having to battle those systems in addition to fighting the demands of food addiction and obesity that I have been battling for what feels like a lifetime.

Thanks, Ms. G.

Some Helpful Resources I Learned From (For Informational Purposes Only)
Life-Changing Drugs You Can’t Afford—The GLP-1 Cost Crisis

Zepbound Dropped by CVS Caremark? How to Keep It Anyway!

How to Afford GLP-1s in 2026? No Insurance, No Coverage!

$50 GLP-1s Start July 1? The Truth About Medicare Coverage

References

Kaiser Family Foundation. (2024). Costly GLP-1 drugs are rarely covered for weight loss by marketplace plans. https://www.kff.org/affordable-care-act/press-release/costly-glp-1-drugs-are-rarely-covered-for-weight-loss-by-marketplace-plans/

Reuters. (2024). Employer coverage of weight-loss drugs rises sharply, survey finds. https://www.reuters.com/business/healthcare-pharmaceuticals/employer-coverage-weight-loss-drugs-rises-sharply-survey-finds-2024-06-13/

WTW. (2024). GLP-1 drugs: Implications for employer health plans. https://www.wtwco.com/en-us/insights/2024/02/glp-1-drugs-implications-for-employer-health-plans